for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seres Therapeutics Inc

MCRB.O

Latest Trade

6.99USD

Change

0.00(0.00%)

Volume

14,511

Today's Range

--

 - 

--

52 Week Range

3.67

 - 

38.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.99
Open
0.00
Volume
14,511
3M AVG Volume
26.40
Today's High
--
Today's Low
--
52 Week High
38.50
52 Week Low
3.67
Shares Out (MIL)
91.68
Market Cap (MIL)
652.74
Forward P/E
-4.72
Dividend (Yield %)
--

Next Event

Q3 2021 Seres Therapeutics Inc Earnings Release

Latest Developments

More

Seres Announces Topline Results For SER-287 Phase 2B Study In Mild-To-Moderate Ulcerative Colitis

Seres Therapeutics Announces FDA Clearance Of Ind For Ser-155

Seres Therapeutics Reports Q1 Loss Per Share $0.39

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Seres Therapeutics Inc

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Industry

Biotechnology & Drugs

Contact Info

200 Sidney St

CAMBRIDGE, MA

02139-4218

United States

+1.617.9459626

http://serestherapeutics.com/

Executive Leadership

Stephen A. Berenson

Independent Chairman of the Board

Eric D. Shaff

President, Chief Executive Officer, Director

David A. Arkowitz

Chief Financial Officer, Executive Vice President, Head of Business Development

John G. Aunins

Executive Vice President - Bioprocess and Manufacturing, Chief Technology Officer

David S. Ege

Executive Vice President, Chief Technology Officer

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.430

2019

-1.240

2020

-1.120

2021(E)

-1.509
Price To Earnings (TTM)
--
Price To Sales (TTM)
21.23
Price To Book (MRQ)
4.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.54
LT Debt To Equity (MRQ)
15.22
Return on Investment (TTM)
-64.57
Return on Equity (TTM)
-50.30

Latest News

Latest News

BRIEF-Seres Therapeutics Reports Q1 2020 Financial Results And Provides Business Updates

* SERES THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Seres Therapeutics Announces Completion Of Enrollment In SER-109 Phase 3 ECOSPOR III Study For Recurrent Clostridium Difficile Infection And Provides Clinical Pipeline Updates

* SERES THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN SER-109 PHASE 3 ECOSPOR III STUDY FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION AND PROVIDES CLINICAL PIPELINE UPDATES

BRIEF-Seres Therapeutics Inc Files For Common Stock Offering Of Up To $25.0 Million - SEC Filing

* SERES THERAPEUTICS INC FILES FOR COMMON STOCK OFFERING OF UP TO $25.0 MILLION - SEC FILING Source text for Eikon: Further company coverage:

BRIEF-Seres Therapeutics Issues Statement Regarding U.S. FDA's March 12, 2020 Safety Alert Related To Use Of Fecal Microbiota Transplantation

* SERES THERAPEUTICS ISSUES STATEMENT REGARDING U.S. FOOD AND DRUG ADMINISTRATION’S MARCH 12, 2020 SAFETY ALERT RELATED TO USE OF FECAL MICROBIOTA TRANSPLANTATION

BRIEF-Seres Therapeutics Files For Mixed Shelf Of Upto $125 Million

* SERES THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $125 MILLION - SEC FILING Source: (http://bit.ly/3aMMsRr) Further company coverage:

BRIEF-Seres Therapeutics Reports Q4 Net Loss Of $18.8 Mln

* SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

BRIEF-Seres Therapeutics Announces Initiation Of Ser-287 Phase 2B Eco-Reset Clinical Study For Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES INITIATION OF SER-287 PHASE 2B ECO-RESET CLINICAL STUDY FOR ULCERATIVE COLITIS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up